FILING ANALYSIS · THURSDAY, NOVEMBER 12
Cardiff Oncology, Inc. CRDF — 8-K: Results of Operations and Financial Condition
neutral
The company's Phase 2 trial for onvansertib in combination with FOLFIRI/bev shows promising results, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm, and all patients remaining in this arm have exceeded 21 months on treatment. However, the recent $10 million registered direct offering may lead to dilution, which could negatively impact the stock price.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →